Are peptides safe?

The short version

Are peptides safe? It depends on three things: which peptide it is, who made it, and whether a clinician looked at your health first.

A few peptides are FDA-approved medicines. They were studied in large trials, and their known side effects are printed on a label, a leaflet that tells the prescriber who should not use them.

Many others have only been studied in animals, so nobody can yet say how safe they are for people.

And a vial sold online as "research use only" comes with no prescriber, no one reviewing your health, and no one answerable for what is in it.

Safety depends on the product, not the word

"Peptide" describes what a molecule is made of: a short chain of amino acids, the building blocks of protein. It tells you nothing about how the product was made, how pure it is, or whether it suits your body. Two vials with the same name on them can carry very different risks.

So the useful question is narrower. Is this an approved medicine, a medicine a licensed pharmacy made to order, or a product sold for lab research? Each one comes with a different amount of checking behind it.

What is known

For the approved medicines, a great deal is known, and that includes the downsides. Semaglutide and tirzepatide, two peptides used for type 2 diabetes and weight, have been studied in thousands of people. Published safety reviews and the official labels list the known problems:

• Stomach upset is the most common: nausea, vomiting, diarrhea or constipation. One safety review of semaglutide put nausea at roughly one patient in three, mostly mild and short-lived.
• Gallbladder problems, such as gallstones, are more common than on a dummy treatment.
• Pancreatitis, a painful swelling of the pancreas, is a warning for this whole group of medicines.
• A thyroid warning comes from studies in rodents. Anyone who has had, or whose close family has had, a rare thyroid cancer called medullary thyroid carcinoma, or a linked condition called MEN 2, is told not to use them.

Known risks are not a reason to panic. They are the reason a prescriber reads your history first.

What is not known

For many of the peptides talked about online, the honest answer is that nobody knows yet.

• BPC-157 has been studied mostly in rats. A 2025 review found only three small pilot studies in people and no large, careful trials. The FDA has written that it lacks enough information to know whether BPC-157 would cause harm when given to humans.
• GHK-Cu has a long record as an ingredient in skin creams. Injected into the body, it has no human studies showing how it behaves.

The FDA's usual worry about injected peptides has two parts. The immune system may treat the peptide as an invader, which doctors call immunogenicity. And it can be hard to confirm exactly what a vial contains.

Why "research use only" is a warning

A research-only label means the seller takes no responsibility for you. No one asks about your conditions, your other medicines or a possible pregnancy. No one is answerable to you for what is in the vial, and it is hard to be sure what it contains.

The FDA has told consumers not to buy semaglutide, tirzepatide and similar weight-loss products labelled "for research purposes" or "not for human consumption" that are sold with dosing instructions. It calls them products of unknown quality that may be harmful. It has also reminded sellers that an injection skips the body's natural barriers against germs and toxins.

What checks of online products have found

Government checks keep turning up the same problems:

• Fake pharmacy labels. The FDA has found compounded semaglutide and tirzepatide sold with false labels. Some labels named pharmacies that turned out not to exist.
• Counterfeit medicine. Fake versions of an approved semaglutide medicine have reached the ordinary U.S. supply chain. Even the needles in the box were counterfeit, so no one could confirm they were sterile.
• Raw ingredients. Of 48 sites the FDA reviewed that make the raw ingredient for GLP-1 medicines, roughly a fifth were failing federal manufacturing rules or had not answered its requests for records.
• Mislabelled parcels. At the port of Cincinnati, border officers seized roughly 5,000 peptide parcels, mislabelled and sent by one shipper in China, between December 2025 and March 2026.
• Research reviews. A 2026 review of peptides used in sport and bodybuilding reported that a largely unregulated supply chain leaves products often mislabelled or contaminated.

Even made-to-order medicines from real pharmacies can go wrong. Poor practice can leave a medicine contaminated, or with more or less of the active ingredient than the label says. In 2012, contaminated steroid injections from one compounding pharmacy made 753 people ill across 20 states, and 64 died. That outbreak is why the rules for sterile, germ-free mixing are strict.

Mix-ups over amounts are another real risk. The FDA has had reports of people drawing up five to 20 times the intended amount from multi-dose vials of compounded semaglutide, and some needed hospital care.

What a clinician checks before prescribing

A proper assessment can start online, but a fixed form on its own is not enough. The Federation of State Medical Boards, the national body for state medical boards, says treatment based solely on a static online questionnaire is not acceptable care. Before prescribing, a clinician will usually want to know:

• Your health history, including past problems such as pancreatitis or gallbladder disease.
• Your family history, for example the rare thyroid cancer mentioned above.
• Every medicine and supplement you take, because peptides can interact with them.
• Pregnancy, breastfeeding or plans to conceive. The labels do not all agree. One approved semaglutide label says to stop at least two months before a planned pregnancy; a tirzepatide label says to stop once a pregnancy is found. Products with no approval have no reviewed pregnancy information at all.

The answer can be no. That is the system working.

If something goes wrong

• Signs of a severe allergic reaction, such as trouble breathing, a swollen face or tongue, or hives, can come on within minutes. Call 911.
• Took the wrong amount? Poison Control is free, confidential and open all day and night on 1-800-222-1222.
• Any new or worrying symptom: tell the clinician who prescribed it.
• Report it to the FDA. Its free MedWatch program takes reports from patients online. The FDA publishes these reports, and points out that a report on its own is not proof that the medicine was the cause.

If you want to understand the legal side of the same question, are peptides legal? covers it in plain words.

A clinician looks first

Promise Peptides is a U.S. telehealth platform. Promise prescribes peptides now through licensed U.S. providers. A licensed U.S. provider reviews every request and your health history, then decides whether to prescribe. Not everyone qualifies, and the answer can be no. Prescribed medicines are prepared by licensed U.S. compounding pharmacies. Each pharmacy separately decides whether it can lawfully prepare a prescription; a prescription does not guarantee it will be filled. Compounded medicines are not FDA-approved. U.S. patients only. Availability varies by state and by treatment. Promise is LegitScript-certified. That certification is not FDA approval.

Visit Promise Peptides for energy

Neo may earn money when readers become Promise patients.

Sources

1. Understanding the Risks of Compounded DrugsU.S. Food and Drug Administration
2. Safety of Semaglutide (Front Endocrinol, 2021)PubMed
3. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review (Drugs, 2026)PubMed
4. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (Curr Rev Musculoskelet Med, 2025)PubMed
5. FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: BPC-157U.S. Food and Drug Administration
6. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration
7. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight LossU.S. Food and Drug Administration
8. Counterfeit MedicineU.S. Food and Drug Administration
9. Import Alert 66-80: GLP-1 Receptor Agonist Bulk Drug SubstancesU.S. Food and Drug Administration
10. Cincinnati CBP foils scheme to smuggle over 5,000 unapproved peptides into the U.S.U.S. Customs and Border Protection
11. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review (J Sports Med Phys Fitness, 2026)PubMed
12. Multistate Outbreak of Fungal Meningitis and Other Infections (archived)U.S. Centers for Disease Control and Prevention
13. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide productsU.S. Food and Drug Administration
14. The Appropriate Use of Telemedicine Technologies in the Practice of MedicineFederation of State Medical Boards
15. Semaglutide injection for type 2 diabetes: prescribing informationDailyMed, U.S. National Library of Medicine
16. Tirzepatide injection for weight management: prescribing informationDailyMed, U.S. National Library of Medicine
17. AnaphylaxisMedlinePlus, U.S. National Library of Medicine
18. Medication errors: What to knowPoison Control (National Capital Poison Center)
19. MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramU.S. Food and Drug Administration
20. FDA Adverse Event Monitoring System (AEMS) Public DashboardU.S. Food and Drug Administration